Dear Valued Visitor,

We have noticed that you are using an ad blocker software.

Although advertisements on the web pages may degrade your experience, our business certainly depends on them and we can only keep providing you high-quality research based articles as long as we can display ads on our pages.

To view this article, you can disable your ad blocker and refresh this page or simply login.

We only allow registered users to use ad blockers. You can sign up for free by clicking here or you can login if you are already a member.

Several Hedge Funds Cut Citigroup $C in Third Quarter

Citigroup (C) lost -38.47% in the third quarter, going from $41.62 a share on June 30 to just $25.61 a share on September 30, and it shows by the number of hedge fund managers that sold out of the company during the third quarter.

Who Sold Citigroup in the Third Quarter?

John Paulson’s Paulson & Co cut its stake in Citigroup during the third quarter. So, did Steve Mandel’s Lone Pine Capital, Paul Ruddock and Steve Heinz‘s Lansdowne Partners, David Tepper’s Appaloosa Management, Lee Ainslie’s Maverick Capital, Jim Chanos’ Kynikos Associates and Bruce Berkowitz’s Fairholme Capital Management.


Deciding to Sell Citigroup

In fairness, it seems they made the right decision. Since then, even with October’s rally and the optimism that seems to have seeped into the market at large, Citigroup is still trading at just $26.83. Compared to competitors like Bank of America (BAC), Citigroup’s outlook appears even more dismal. Since the end of the third quarter, Citigroup has returned 9.41% while BAC has returned 0.16%  and Citigroup may carry a slightly higher analyst recommendation (2.2 on a 5 point scale where 1 means buy) than rival BAC (it has a mean recommendation of 2.4) but that is an average recommendation. Of 25 analysts, 3 recommend Citigroup as underperform or sell compared to BAC, which had just 1 of 32 analysts recommend underpeform and none recommend selling the stock. BAC has greater revenue ($75.36B to C’s $65.78B) in spite of having the smaller market cap  – BAC has a market cap of just $59.08B compared to Citigroup’s $78.35B. BAC also has higher 5-year growth estimates (11.75% to C’s 11.66%).

Biotech Stock Alert - 20% Guaranteed Return in One Year

Hedge Funds and Insiders Are Piling Into

One of 2015's best hedge funds and two insiders snapped up shares of this medical device stock recently. We believe its transformative and disruptive device will storm the $3+ billion market and help it achieve 500%-1000% gains in 3 years.

Get your FREE REPORT and the details of our 20% return guarantee today.

Subscribe me to Insider Monkey's Free Daily Newsletter
This is a FREE report from Insider Monkey. Credit Card is NOT required.
Loading Comments...

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 102% in 3 years!! Wondering How?

Download a complete edition of our newsletter for free!